Logo

Rigel Pharmaceuticals' Tavalisse (fostamatinib disodium hexahydrate) Receives FDA Approval for Chronic Immune Thrombocytopenia (ITP) in Adults

Share this

Rigel Pharmaceuticals' Tavalisse (fostamatinib disodium hexahydrate) Receives FDA Approval for Chronic Immune Thrombocytopenia (ITP) in Adults

Shots:

  • The approval is based on three FIT studies results assessing Tavalisse (100/150mg- bid) vs Placebo in 150 patients with chronic ITP in ratio 2:1
  • The FIT studies result: FIT-1 (NCT02076399) stable platelets response (SPR) (18% vs 0%); FIT-2 (NCT02076412) SPR (16% vs 4%); FIT-3 (23%)
  • Tavalisse (fostamatinib disodium hexahydrate- PO) is a spleen tyrosine kinase (SYK) inhibitor and has received OD designation in Jan-2018

Ref: Rigel | Image: Glassdoor

Click here to­ read the full press release 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions